Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Duloxetine for the Treatment of Dysthymia

This study has been completed.
Eli Lilly and Company
Information provided by:
Stanford University Identifier:
First received: September 9, 2005
Last updated: April 7, 2009
Last verified: April 2009
The purpose of this study is to test the hypothesis that duloxetine (Cymbalta), in doses of 60 or 120 mg/day, is an effective and tolerable treatment for adult outpatients suffering from dysthymia. Dysthymia is chronic, mild depression characterized by feeling sad or low more days than not for more than 2 years.

Condition Intervention
Depressive Disorder
Drug: duloxetine

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Duloxetine for the Treatment of Dysthymia

Resource links provided by NLM:

Further study details as provided by Stanford University:

Primary Outcome Measures:
  • Inventory of Depressive Symptomatology (Clinician-Rated)

Secondary Outcome Measures:
  • Clinical Global Impressions - Improvement
  • Zung Self-Rating Depression Scale
  • Patient Global Improvement
  • Brief Pain Inventory
  • WHO-QOL 100

Estimated Enrollment: 24
Study Start Date: September 2004
Study Completion Date: April 2006
Primary Completion Date: April 2006 (Final data collection date for primary outcome measure)
Detailed Description:

The purpose of this research is to obtain information on the safety and effectiveness of duloxetine (Cymbalta) in the treatment of dysthymia. Duloxetine has been approved by the federal Food and Drug Administration for the treatment of depression. The use of duloxetine for treatment of dysthymia is considered experimental.

Dysthymia is defined as chronic, low-grade depression, characterized by feeling low or depressed, that lasts for two or more years. Additional symptoms may include: poor appetite or overeating; insomnia or sleeping too much; low energy or fatigue; low self-esteem; poor concentration or difficulty making decisions; and feelings of hopelessness.

Dysthymia affects 3-6% of the general population, but is an underdiagnosed and undertreated disorder. In double-blind, placebo-controlled clinical trials of antidepressant medications, dysthymia response rates are around 60%, compared to an average placebo response rate of about 30%. Duloxetine has not been studied in the treatment of dysthymia, but has shown results in the treatment of major depression. In a 9-week, double-blind, placebo-controlled study of 257 patients with major depression, 65% responded to duloxetine 60mg/day, compared to 43% to placebo. Based on these results, it is highly likely that duloxetine will be an effective treatment for dysthymia.

This research study is being conducted at Stanford University Medical Center with a total of 24 patients, age 18 and above, with dysthymia.

In the study, subjects will receive duloxetine for 12 weeks. This is an open-label study, which means that every subject receives the study medication.

In total, subjects are seen for 10 visits across 13 weeks. At each visit subjects' heart rate, blood pressure and weight measurements will be obtained. At each visit study personnel will interview subjects about their symptoms, monitor side effects and ask them to complete study questionnaires.

Beginning at the second visit, subjects receive duloxetine 60 mg/day. If they experience side effects, the dose can be decreased to 30 mg/day for several days, but will be increased back to 60 mg/day by the end of the first week. If subjects are unable to tolerate a dose of 60 mg/day due to side effects, they will be withdrawn from the study. At the end of 6 weeks, if they have not responded to the study medication (as determined by doctor ratings based on subjects' reports), the dose of duloxetine will be increased to 120 mg/day, unless subjects are experiencing troubling side effects. Subjects continue on the minimum dose that brings about remission or the maximum tolerated dose for the remaining 6 weeks. Medication dosing will be flexible and determined by tolerance (side effects) and therapeutic effect.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria::

  • Sign an informed consent form
  • 18 years of age or older
  • Females not pregnant or breastfeeding or planning pregnancy and using an acceptable form of contraception
  • Meet DSM-IV criteria for dysthymia
  • A screening IDS-C score of 17 or greater
  • No history of serious or unstable medical disorder
  • Not taking any significant concurrent medications
  • Not currently receiving psychotherapy

Exclusion Criteria:- Suffering from DSM-IV defined

  • delirium, dementia, amnestic, or other cognitive disorders
  • mental disorders due to a general medical condition
  • factitious or somatoform disorders
  • mental retardation or developmental disabilities
  • substance or alcohol abuse within the last 3 months
  • depressive disorders with current suicidal risk
  • psychotic disorders including delusional disorder, somatic type
  • dissociative disorder
  • personality disorders sufficiently severe to interfere with study participation
  • History of DSM-IV defined bipolar I or II disorder
  • History of non-response of dysthymia to adequate antidepressant medication
  • History of major depression refractory to two adequate trials of antidepressants
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00185575

United States, California
Stanford University School of Medicine
Stanford, California, United States, 94305
Sponsors and Collaborators
Stanford University
Eli Lilly and Company
Principal Investigator: Lorrin M Koran Stanford University
  More Information

Responsible Party: Lorrin M Koran, Principal Investigator, Stanford University School of Medicine Identifier: NCT00185575     History of Changes
Other Study ID Numbers: SUSPO30478
Study First Received: September 9, 2005
Last Updated: April 7, 2009

Additional relevant MeSH terms:
Depressive Disorder
Mood Disorders
Mental Disorders
Behavioral Symptoms
Duloxetine Hydrochloride
Serotonin and Noradrenaline Reuptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents
Antidepressive Agents
Psychotropic Drugs
Dopamine Agents processed this record on April 28, 2017